OptimizeRx Corp 8-K

What Happened
OptimizeRx Corporation (OPRX) filed a Form 8-K reporting that on April 3, 2026 the Board appointed Mary Varghese Presti as an independent director, effective immediately. Her appointment expands the Board from six to seven members and she was also named a member of the Audit Committee. The company issued a press release dated April 8, 2026 announcing the appointment; the 8-K was filed April 9, 2026.

Key Details

• Appointment date: April 3, 2026; press release dated April 8, 2026; Form 8-K filed April 9, 2026.
• Board size increased from six to seven members.
• Ms. Varghese Presti will serve until the 2026 annual meeting and until her successor is elected and qualified.
• Director compensation (non-employee program): $45,000 annual cash retainer, approximately $175,000 annual equity grant value, plus $10,000 additional cash retainer for Audit Committee membership.

Why It Matters
This is a governance update: adding an independent director and Audit Committee member can strengthen board oversight and committee capacity, which investors watch for corporate governance and risk controls. The filing does not report changes to executive officers or any financial results; it documents the board refresh and the standard non-employee director compensation tied to the appointment.